Sec. 783. Strengthening clinical research funding for tuberculosis
261 words·~1 min read·
/bill/115/s/3660/is/section-783A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Secretary of Health and Human Services shall expand and intensify support for current and prospective research activities of the National Institutes of Health, the Biomedical Advanced Research and Development Authority, and the Centers for Disease Control and Prevention Division of Tuberculosis Elimination to develop new therapeutics, diagnostics, vaccines, and other prevention modalities in addressing all forms of tuberculosis (referred to in this section as TB ). Research activities under subsection
(a)shall include— research to develop novel, safe drugs and drug regimens for the treatment of TB, including in adolescent and pediatric populations and in pregnant and lactating women; research to develop rapid diagnostic tests for all forms of TB, including diagnostics that can be used for pediatric populations and people living with HIV, diagnostics that can detect extra pulmonary TB and drug resistance, and diagnostics that can be used at the point of care; research to advance basic knowledge of the pathogenesis of TB and its major comorbidities, including HIV and diabetes mellitus; research to improve knowledge and understandings of the role of latency in TB and the factors that increase the risk of latent TB infection progressing to active, symptomatic TB disease; awarding grants and contracts to specifically develop new and needed vaccines to address TB; awarding grants and contracts to support the training and development of clinical researchers whose research improves the landscape of tools to combat TB; and awarding grants and contracts to support capacity-building and develop clinical trial site infrastructure in the United States and in TB endemic countries to support the aforementioned research activities.